GORE® CARDIOFORM Septal Occluder Migraine Clinical Study | MicrobiomeTrials← Back to trialsNCT04100135
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
TERMINATEDNAINTERVENTIONAL
Trial Details
Start: 2021-02-05Est. Completion: 2024-08-15
Enrollment target: 7 participants Locations- Mayo Clinic Arizona, Phoenix, Arizona, United States
- UCLA Health, Los Angeles, California, United States
- Santa Barbara Cottage Hospital Research Institute, Santa Barbara, California, United States
- South Denver Cardiology, Denver, Colorado, United States
- Medical Center of the Rockies, Loveland, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Mercy One Iowa Heart Center, West Des Moines, Iowa, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- University at Buffalo, Buffalo, New York, United States
- SJH Cardiology Associates, Liverpool, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Aurora St Luke's Medical Center, Milwaukee, Wisconsin, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Eye Pain
Approximately 20% of Veterans have a diagnosis of dry eye (DE) syndrome which is often accompanied by ocular pain that s…
Miami, United StatesCompleted Nov 30, 2024
Temporomandibular Disorder
Temporomandibular disorders (TMD) encompass a group of conditions involving the masticatory muscles, temporomandibular j…
Ridgeland, United StatesEst. completion Jan 1, 2027
Menstrual Migraine
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstru…
Phoenix, United StatesEst. completion Nov 29, 2026